Literature DB >> 300866

Atypical phenylketonuria with normal phenylalanine hydroxylase and dihydropteridine reductase activity in vitro.

K Bartholomé, D J Byrd, S Kaufman, S Milstien.   

Abstract

A child with phenylketonuria had normal phenylalanine hydroxylase activity in vitro. In addition, all known components of the phenylalanine hydroxylating system were within the normal range. Despite early treatment with a phenylalanine-restricted diet, the patient developed severe neurological symptoms. Although the primary molecular defect in this child is not known, there are indications that the defect lead to disturbances in phenylalanine metabolism and the biosynthesis of L-dopa and L-5-hydroxytryptophan. The administration of these two precursors of neurotransmitters brought a notable improvement in the patient's neurological symptoms.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 300866

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  22 in total

1.  Malignant hyperphenylalaninaemia--current status (June 1977).

Authors:  D M Danks; K Bartholomé; B E Clayton; H Curtius; H Gröbe; S Kaufman; R Leeming; W Pfleiderer; H Rembold; F Rey
Journal:  J Inherit Metab Dis       Date:  1978       Impact factor: 4.982

2.  Treatment and outcome of Taiwanese patients with 6-pyruvoyltetrahydropterin synthase gene mutations.

Authors:  Y H Chien; S C Chiang; A Huang; J M Lin; Y N Chiu; S P Chou; S Y Chu; T R Wang; W L Hwu
Journal:  J Inherit Metab Dis       Date:  2001-12       Impact factor: 4.982

3.  Hyperphenylalaninaemia due to dihydropteridine reductase deficiency.

Authors:  H Gröbe; K Bartholome; S Milstien; S Kaufman
Journal:  Eur J Pediatr       Date:  1978-09-08       Impact factor: 3.183

4.  Atypical PKU with normal phenylalanine hydroxylase and dihydropteridine reductase activity in vitro.

Authors:  R J Leeming; I Smith
Journal:  Arch Dis Child       Date:  1979-02       Impact factor: 3.791

5.  Hyperphenylalaninemia due to impaired dihydrobiopterin biosynthesis.

Authors:  T Tanaka; K Aihara; K Iwai; M Kohashi; K Tomita; K Narisawa; N Arai; H Yoshida; T Usui
Journal:  Eur J Pediatr       Date:  1981-07       Impact factor: 3.183

6.  Respiratory function after repair of congenital diaphragmatic hernia.

Authors:  J Battin; M Colle; T Bechraoui
Journal:  Arch Dis Child       Date:  1977-12       Impact factor: 3.791

7.  Human dihydropteridine reductase: characterisation of a cDNA clone and its use in analysis of patients with dihydropteridine reductase deficiency.

Authors:  H H Dahl; W Hutchison; W McAdam; S Wake; F J Morgan; R G Cotton
Journal:  Nucleic Acids Res       Date:  1987-03-11       Impact factor: 16.971

8.  Biopterin synthesis defect. Treatment with L-dopa and 5-hydroxytryptophan compared with therapy with a tetrahydropterin.

Authors:  R R McInnes; S Kaufman; J J Warsh; G R Van Loon; S Milstien; G Kapatos; S Soldin; P Walsh; D MacGregor; W B Hanley
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

9.  Dihydrobiopterin biosynthesis deficiency.

Authors:  J L Dhondt; B Leroux; J P Farriaux; C Largilliere; R J Leeming
Journal:  Eur J Pediatr       Date:  1983-12       Impact factor: 3.183

10.  GTP cyclohydrolase I deficiency, a new enzyme defect causing hyperphenylalaninemia with neopterin, biopterin, dopamine, and serotonin deficiencies and muscular hypotonia.

Authors:  A Niederwieser; N Blau; M Wang; P Joller; M Atarés; J Cardesa-Garcia
Journal:  Eur J Pediatr       Date:  1984-02       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.